INT131 PPAR-gamma Agonist Neuroprotection Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for multiple sclerosis (MS) relapses are poorly tolerated due to adverse effects and do not provide overall neuroprotection, leaving a need for a safe and effective method to slow progression and alleviate symptoms.
Innovation Solution
Administration of INT131, a selective PPARγ agonist that activates anti-inflammatory and neuroprotective gene pathways, which has been shown to be effective in treating MS relapses by reducing inflammation and neurodegeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current MS therapies are administered, then relapse frequency and severity are reduced, but adverse effects increase and neuroprotection is not provided
Solution Approach 1:
The patent changes the pharmacological parameter by using a PPAR-gamma agonist instead of conventional MS therapies. This parameter change results in both effectiveness in reducing relapse frequency and severity, and additional neuroprotective effects without the adverse effects associated with current treatments.
2Object-generated harmful factors
If conventional MS treatments are used, then immune system activity is suppressed, but overall neuroprotection is not achieved
Solution Approach 1:
The PPAR-gamma agonist INT131 performs multiple functions simultaneously: it suppresses immune-mediated inflammation and provides neuroprotection. This multi-functionality resolves the contradiction by achieving both immune suppression and neuroprotection with a single therapeutic agent.
Data Source
Figure 1~2
Figure 3
AI summary
Methods of treatment of multiple sclerosis (MS) with PPARγ agonists, and in particular with the compound of formula (I) known as INT131.